UY31531A1 - Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) - Google Patents
Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)Info
- Publication number
- UY31531A1 UY31531A1 UY31531A UY31531A UY31531A1 UY 31531 A1 UY31531 A1 UY 31531A1 UY 31531 A UY31531 A UY 31531A UY 31531 A UY31531 A UY 31531A UY 31531 A1 UY31531 A1 UY 31531A1
- Authority
- UY
- Uruguay
- Prior art keywords
- therapy
- pharmaceutical compositions
- oxoadenine
- tlr
- contain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
La invencion estipula sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9H-purin-9-il)propil(3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo, composiciones farmacéuticas que las contienen y su uso en terapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1416407P | 2007-12-17 | 2007-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31531A1 true UY31531A1 (es) | 2009-08-03 |
Family
ID=40795767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31531A UY31531A1 (es) | 2007-12-17 | 2008-12-15 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) |
Country Status (26)
Country | Link |
---|---|
US (1) | US8673907B2 (es) |
EP (1) | EP2235018A4 (es) |
JP (1) | JP5557748B2 (es) |
KR (2) | KR20160085360A (es) |
CN (1) | CN101903389B (es) |
AR (1) | AR069780A1 (es) |
AU (1) | AU2008339095B2 (es) |
BR (1) | BRPI0821020A2 (es) |
CA (1) | CA2709126C (es) |
CL (1) | CL2008003750A1 (es) |
CO (1) | CO6280403A2 (es) |
CR (1) | CR11507A (es) |
CU (1) | CU23932B1 (es) |
EA (1) | EA017532B1 (es) |
EC (1) | ECSP10010265A (es) |
HN (1) | HN2010001235A (es) |
IL (1) | IL206039A0 (es) |
NI (1) | NI201000104A (es) |
NZ (1) | NZ585961A (es) |
PE (1) | PE20091156A1 (es) |
SV (1) | SV2010003596A (es) |
TW (1) | TWI424848B (es) |
UA (1) | UA100996C2 (es) |
UY (1) | UY31531A1 (es) |
WO (1) | WO2009078798A1 (es) |
ZA (1) | ZA201003877B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092893A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9置換−8−オキソアデニン化合物 |
TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
JP5480637B2 (ja) | 2007-03-19 | 2014-04-23 | アストラゼネカ・アクチエボラーグ | Toll様受容体(tlr7)モジュレーターとしての9−置換−8−オキソ−アデニン化合物 |
EP2139894B1 (en) | 2007-03-19 | 2011-10-26 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
WO2008114819A1 (ja) | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
KR20100125245A (ko) * | 2008-01-17 | 2010-11-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 아데닌 화합물의 제조 방법 |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
ES2623794T3 (es) * | 2008-12-09 | 2017-07-12 | Gilead Sciences, Inc. | Intermedios para la preparación de moduladores de receptores tipo toll |
GB0908772D0 (en) | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
IN2012DN02984A (es) | 2009-10-22 | 2015-07-31 | Gilead Sciences Inc | |
KR101773541B1 (ko) * | 2010-02-10 | 2017-08-31 | 글락소스미스클라인 엘엘씨 | 6-아미노-2-{[(1s)-1-메틸부틸]옥시}-9-[5-(1-피페리디닐)-7,9-디하이드로-8h-퓨린-8-온 말레이트 |
EP2651937B8 (en) | 2010-12-16 | 2016-07-13 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy |
WO2012080730A1 (en) | 2010-12-17 | 2012-06-21 | Astrazeneca Ab | Purine derivatives |
BR112014001425A2 (pt) | 2011-07-22 | 2017-11-21 | Glaxosmithkline Llc | forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo |
ES2644702T3 (es) | 2012-05-18 | 2017-11-30 | Sumitomo Dainippon Pharma Co., Ltd. | Compuestos de ácido carboxílico |
SG11201500787YA (en) | 2012-08-24 | 2015-03-30 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
RS56233B1 (sr) | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nova jedinjenja |
RU2640200C2 (ru) | 2012-11-20 | 2017-12-27 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
CA2890201A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1375162A (es) | 1970-10-22 | 1974-11-27 | ||
US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
GB1546937A (en) | 1976-07-29 | 1979-05-31 | Beecham Group Ltd | 2,4-diaminopyrimidine derivatives |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
HU201675B (en) * | 1983-08-26 | 1990-12-28 | Ivan Balkanyi | Process for producing oral pharmaceutical compositions with unappetizing effect |
SE8404768L (sv) | 1983-09-27 | 1985-03-28 | Ceskoslovenska Akademie Ved | 9-(aminoalkyl)-8-hydroxiadeniner och sett for deras framstellning |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
DE3603577A1 (de) | 1986-02-06 | 1987-08-13 | Joachim K Prof Dr Seydel | Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit |
CA2141192C (en) * | 1992-07-28 | 1999-02-02 | Roberta C. Bloom | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
US5543407A (en) * | 1992-09-30 | 1996-08-06 | Ningbo Institute Of Microcirculation And Henbane | Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent |
JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
KR100330942B1 (ko) * | 1994-03-02 | 2002-11-16 | 악조 노벨 엔.브이. | 설하또는협측투여용약학조성물 |
US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
MX9702488A (es) | 1994-10-05 | 1998-04-30 | Darwin Discovery Ltd | Compuestos de purina y guanina como inhibidores de pnp. |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
US6028076A (en) | 1996-07-03 | 2000-02-22 | Japan Energy Corporation | Purine derivative |
US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
CA2212449C (en) * | 1997-08-07 | 2001-11-06 | Brantford Chemicals Inc. | Improved preparation of 1,2,5,6-tetrahydro-3-carboalkoxypyridines such as arecoline and salts of 1,2,5,6-tetrahydro-3-carboalkoxypyridines and arecoline hydrobromide |
EP1035123B1 (en) | 1997-11-28 | 2003-08-20 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
JPH11187245A (ja) | 1997-12-17 | 1999-07-09 | M Ken:Kk | デジタル画像処理方法、デジタル画像処理装置及び、デジタル画像処理プログラムを記録した記録媒体 |
JPH11179507A (ja) | 1997-12-17 | 1999-07-06 | Kawasaki Steel Corp | 連続鋳造用鋳型の振動方法 |
JPH11180981A (ja) | 1997-12-19 | 1999-07-06 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
JP4160645B2 (ja) | 1997-12-24 | 2008-10-01 | 大日本住友製薬株式会社 | 新規アデニン誘導体及びその医薬用途 |
JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
CA2341707C (en) | 1998-08-27 | 2010-02-16 | Sumitomo Pharmaceuticals Co., Ltd. | Pyrimidine derivatives |
JP2000159767A (ja) | 1998-11-26 | 2000-06-13 | Sumitomo Pharmaceut Co Ltd | 8−ヒドロキシアデニン誘導体の新規製造法 |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
KR20030031500A (ko) * | 2000-06-20 | 2003-04-21 | 아테로제닉스, 인코포레이티드 | 1,3-비스-(치환된-페닐)-2-프로펜-1-온 및 vcam-1매개된 질환을 치료하기 위한 그의 용도 |
US6630478B2 (en) | 2000-07-07 | 2003-10-07 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy |
US20020040032A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
US20020128264A1 (en) | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
AU2002239277A1 (en) | 2000-11-20 | 2002-05-27 | Cor Therapeutics, Inc. | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
KR100892614B1 (ko) | 2001-04-17 | 2009-04-09 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 유도체 |
IN192057B (es) * | 2001-07-19 | 2004-02-14 | Ranbaxy Lab Ltd | |
ITRM20010465A1 (it) | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US20060252774A1 (en) | 2002-05-02 | 2006-11-09 | Vatner Stephen F | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases |
JP2005533822A (ja) * | 2002-06-27 | 2005-11-10 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | 臭化水素酸カルベジロール |
JPWO2004003198A1 (ja) | 2002-06-27 | 2005-10-27 | 株式会社ジェノックス創薬研究所 | アレルギー性疾患の検査方法、および治療のための薬剤 |
WO2004011481A1 (ja) | 2002-07-30 | 2004-02-05 | Sankyo Co | ホスミドシン誘導体及びその製造方法 |
BR0314761A (pt) | 2002-09-27 | 2005-07-26 | Sumitomo Pharma | Composto de adenina e seu uso |
JP2004137157A (ja) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | 新規アデニン誘導体を有効成分として含有する医薬 |
US7167750B2 (en) * | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
KR20060016817A (ko) | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | 소분자 톨-유사 수용체 (tlr) 길항제 |
OA13310A (en) * | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
JP2005089334A (ja) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | 8−ヒドロキシアデニン化合物 |
ITMI20040146A1 (it) * | 2004-01-30 | 2004-04-30 | Acraf | Ibopamina maleato metodo per prepararlo e composizioni farmaceutiche che lo comprendono |
WO2005092892A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
WO2005092893A1 (ja) * | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9置換−8−オキソアデニン化合物 |
KR20070012675A (ko) * | 2004-04-20 | 2007-01-26 | 사노피-아벤티스 | 메틸(+)-(S)-α-(2-클로로페닐)-6,7-디히드로티에노[3,2-C]피리딘-5(4H) 아세테이트 히드로브로마이드, 클로피도그렐히드로브로마이드의 다형성 형태 |
BRPI0611435A2 (pt) | 2005-05-04 | 2010-09-08 | Pfizer Ltd | derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos |
WO2006129784A1 (ja) | 2005-06-03 | 2006-12-07 | Riken | インターフェロン-α制御剤 |
US7645802B2 (en) * | 2005-06-27 | 2010-01-12 | Biovail Laboratories International Srl. | Bupropion hydrobromide and therapeutic applications |
WO2007024707A2 (en) | 2005-08-22 | 2007-03-01 | The Regents Of The University Of California | Tlr agonists |
TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
JPWO2007034916A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
US20090192153A1 (en) | 2005-09-22 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
US20080269240A1 (en) | 2005-09-22 | 2008-10-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel Adenine Compound |
EP1939202A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW COMPOUND OF ADENINE |
JPWO2007034917A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
EP1948608B1 (en) * | 2005-11-08 | 2012-03-14 | Millennium Pharmaceuticals, Inc. | Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor |
EP1891034A2 (en) * | 2005-12-27 | 2008-02-27 | Teva Pharmaceutical Fine Chemicals S.R.L. | Processes for preparing darifenacin hydrobromide |
US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
BRPI0707945A2 (pt) | 2006-02-17 | 2011-05-17 | Pfizer Ltd | derivados de 3-deazapurina como modulares de tlr7 |
US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
WO2008005555A1 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
US20100168245A1 (en) * | 2006-08-10 | 2010-07-01 | Wainer Irving W | Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
HUP0600868A3 (en) * | 2006-11-24 | 2009-03-30 | Richter Gedeon Nyrt | 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation |
EP2104491B1 (en) * | 2006-12-06 | 2017-02-22 | Janssen Sciences Ireland UC | Hydrobromide salt of an anti-hiv compound |
TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
EP2016076A2 (en) * | 2007-01-22 | 2009-01-21 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof |
TW200843779A (en) | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
EP2139894B1 (en) | 2007-03-19 | 2011-10-26 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
JP5480637B2 (ja) | 2007-03-19 | 2014-04-23 | アストラゼネカ・アクチエボラーグ | Toll様受容体(tlr7)モジュレーターとしての9−置換−8−オキソ−アデニン化合物 |
TW200902018A (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
WO2008114819A1 (ja) | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2008137134A2 (en) * | 2007-05-01 | 2008-11-13 | Teva Pharmaceuticals Usa, Inc. | Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide |
PL2155743T3 (pl) | 2007-05-08 | 2013-01-31 | Astrazeneca Ab | Imidazochinoliny o właściwościach immunomodulacyjnych |
KR101561710B1 (ko) | 2007-06-29 | 2015-10-19 | 길리애드 사이언시즈, 인코포레이티드 | 퓨린 유도체 및 그것의 톨 유사 수용체 7의 조절 인자로서 용도 |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
KR20100125245A (ko) | 2008-01-17 | 2010-11-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 아데닌 화합물의 제조 방법 |
US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
GB0908772D0 (en) | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
JP2013512859A (ja) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
-
2008
- 2008-12-15 UY UY31531A patent/UY31531A1/es not_active Application Discontinuation
- 2008-12-15 PE PE2008002077A patent/PE20091156A1/es not_active Application Discontinuation
- 2008-12-16 KR KR1020167017472A patent/KR20160085360A/ko active IP Right Grant
- 2008-12-16 CL CL2008003750A patent/CL2008003750A1/es unknown
- 2008-12-16 EP EP08862259A patent/EP2235018A4/en not_active Withdrawn
- 2008-12-16 WO PCT/SE2008/051465 patent/WO2009078798A1/en active Application Filing
- 2008-12-16 CA CA2709126A patent/CA2709126C/en not_active Expired - Fee Related
- 2008-12-16 JP JP2010539378A patent/JP5557748B2/ja not_active Expired - Fee Related
- 2008-12-16 UA UAA201006376A patent/UA100996C2/ru unknown
- 2008-12-16 NZ NZ585961A patent/NZ585961A/en not_active IP Right Cessation
- 2008-12-16 EA EA201001014A patent/EA017532B1/ru not_active IP Right Cessation
- 2008-12-16 US US12/808,627 patent/US8673907B2/en not_active Expired - Fee Related
- 2008-12-16 KR KR1020107013267A patent/KR20100093566A/ko not_active Application Discontinuation
- 2008-12-16 BR BRPI0821020-9A patent/BRPI0821020A2/pt not_active IP Right Cessation
- 2008-12-16 CN CN2008801211854A patent/CN101903389B/zh not_active Expired - Fee Related
- 2008-12-16 AU AU2008339095A patent/AU2008339095B2/en not_active Ceased
- 2008-12-16 TW TW097148921A patent/TWI424848B/zh not_active IP Right Cessation
- 2008-12-17 AR ARP080105494A patent/AR069780A1/es unknown
-
2010
- 2010-05-27 IL IL206039A patent/IL206039A0/en unknown
- 2010-05-27 CO CO10063975A patent/CO6280403A2/es not_active Application Discontinuation
- 2010-05-31 ZA ZA2010/03877A patent/ZA201003877B/en unknown
- 2010-06-17 CR CR11507A patent/CR11507A/es unknown
- 2010-06-17 SV SV2010003596A patent/SV2010003596A/es unknown
- 2010-06-17 HN HN2010001235A patent/HN2010001235A/es unknown
- 2010-06-17 CU CU2010000123A patent/CU23932B1/es not_active IP Right Cessation
- 2010-06-17 NI NI201000104A patent/NI201000104A/es unknown
- 2010-06-17 EC EC2010010265A patent/ECSP10010265A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31531A1 (es) | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
DK1791571T3 (da) | Radiofluorinerede peptider | |
EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
CL2011001392A1 (es) | Compuestos derivados de pteridinona, moduladores de receptores tipo toll; composicion farmaceutica que lo comprende, util en el tratamiento de una infeccion viral, cancer, asma, entre otras. | |
DK2061886T3 (da) | Små kationiske immunomodulerende peptider | |
EA200802008A1 (ru) | Фармацевтические композиции | |
BRPI0810863A2 (pt) | Uso de hidrolisados de proteína para estabilizar formulações de detergente de metaloprotease. | |
MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
DK1877409T3 (da) | Substituerede pyrrolopyridiner, sammensætninger, der indeholder samme, fremgangsmåde til fremstilling deraf samt anvendelse deraf | |
BRPI0608604B8 (pt) | moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
MA32190B1 (fr) | Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation | |
DK1928409T3 (da) | Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid | |
HN2006035237A (es) | Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas | |
DK1852022T3 (da) | Kunstigt hår samt paryk, der anvender dette | |
BRPI0819299A2 (pt) | Uso de composição, e, composição contendo proteína | |
BRPI1013259B8 (pt) | moduladores lxr | |
DE602005017216D1 (de) | Hybrides Tintenzuführsystem | |
BRPI0620985B8 (pt) | composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina | |
BRPI0817053A2 (pt) | Formulações farmacêuticas de orlistat | |
ECSP10010576A (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
BRPI0820388A2 (pt) | Molécula concatenada para a modulação da atividade do sistema imunológico humano e animal, composição, kit, fármaco e uso | |
UY31427A1 (es) | Derivados 1,2,4-triazol amino como moduladores de mglur5 | |
DK2207808T3 (da) | Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20171019 |